Emboline — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Emboline is a clinical-stage medical device company targeting the significant unmet need for embolic protection during transcatheter cardiovascular procedures. Its flagship product, the Emboliner system, is engineered to provide comprehensive 'total-body' protection by capturing debris before it can travel to the brain, kidneys, and other organs. The company has completed enrollment in a pivotal 500-patient IDE trial comparing Emboliner to the market-leading Sentinel device, with data expected to support regulatory filings for FDA approval and CE Mark in Europe.

Cardiovascular

Technology Platform

The Emboliner® is a catheter-based, dual-layer Nitinol mesh filter system designed for total-body embolic protection during transcatheter heart procedures. It is engineered to capture debris in the descending aorta, balancing high blood flow with superior particle capture, and features an integrated port for debris removal.

Opportunities

The massive and growing global TAVR procedure volume represents a multi-billion dollar addressable market for embolic protection.

Emboline's total-body protection thesis addresses the growing clinical concern over systemic embolic complications beyond just stroke, including cognitive decline and kidney injury, potentially establishing a new standard of care.

The technology platform could also be expanded to other transcatheter cardiovascular procedures like mitral valve interventions.

Risk Factors

The company faces high clinical and regulatory risk, as its pivotal trial must successfully demonstrate safety and effectiveness against the established market leader.

Commercialization risk is significant, requiring displacement of an entrenched competitor and securing favorable reimbursement.

Technological evolution in valve design or procedure technique could potentially reduce the future need for adjunctive protection devices.

Competitive Landscape

The dominant competitor is Boston Scientific with its Sentinel Cerebral Protection System, the only FDA-approved device specifically for cerebral embolic protection during TAVR. Emboline's strategy is one of displacement, arguing that total-body protection is clinically superior to cerebral-only protection. Other potential competitors include companies developing alternative filter technologies or integrated valve/protection systems, but the market is currently a near-monopoly.

More companies in Drug Delivery & Formulation →More companies in United States →